June 8, 2020 / 5:07 AM / a month ago

BRIEF-Oasmia Pharmaceutical Signs Phase 1B Trial Agreement With SAKK

June 8 (Reuters) - Oasmia Pharmaceutical AB:

* OASMIA PHARMACEUTICAL AB SIGNS PHASE 1B TRIAL AGREEMENT WITH SAKK, THE SWISS GROUP FOR CLINICAL CANCER RESEARCH FOR EVALUATION OF DOCETAXEL MICELLAR

* PARTNERED WITH SWISS GROUP FOR CLINICAL CANCER RESEARCH (SAKK) TO CONDUCT FIRST CLINICAL TRIAL OF OASMIA’S DOCETAXEL MICELLAR COMPOUND IN ADVANCED PROSTATE CANCER Source text for Eikon: Further company coverage: (Gdansk Newsroom)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below